标题
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
作者
关键词
-
出版物
Expert Review of Clinical Pharmacology
Volume 11, Issue 4, Pages 345-359
出版商
Informa UK Limited
发表日期
2018-02-26
DOI
10.1080/17512433.2018.1445966
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma
- (2018) Howard L Kaufman et al. Future Oncology
- Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
- (2018) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection
- (2017) Ata S. Moshiri et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients
- (2017) J.K. Winkler et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
- (2017) Renee N. Donahue et al. Journal for ImmunoTherapy of Cancer
- Milestones in the Staging, Classification, and Biology of Merkel Cell Carcinoma
- (2017) Ata S. Moshiri et al. Journal of the National Comprehensive Cancer Network
- PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma
- (2016) J.K. Winkler et al. BRITISH JOURNAL OF DERMATOLOGY
- Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study
- (2016) Kelly G. Paulson et al. CANCER
- Genomic Approaches to Understanding Response and Resistance to Immunotherapy
- (2016) D. A. Braun et al. CLINICAL CANCER RESEARCH
- Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma
- (2016) Laurence Feldmeyer et al. CLINICAL CANCER RESEARCH
- Merkel Cell Carcinoma Therapeutic Update
- (2016) Nicole M. Cassler et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.
- (2016) Tomohiro Nishina et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to M.C. Chamberlain and T.J. Kruser
- (2016) Claire F. Verschraegen et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete spontaneous regression of Merkel cell carcinoma (1986-2016): a 30 year perspective
- (2016) Noreen M. Walsh JOURNAL OF CUTANEOUS PATHOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
- (2016) Ricardo Costa et al. Oncotarget
- Merkel cell polyomavirus infection and Merkel cell carcinoma
- (2016) Wei Liu et al. Current Opinion in Virology
- Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
- (2016) Jayasri G. Iyer et al. Cancer Medicine
- Metastatic Merkel cell carcinoma response to nivolumab
- (2016) Frances M. Walocko et al. Journal for ImmunoTherapy of Cancer
- Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma
- (2016) Cathrin Ritter et al. Scientific Reports
- Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
- (2015) C. L. Freeman et al. BLOOD
- The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma
- (2015) Paul William Harms et al. CANCER RESEARCH
- UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas
- (2015) S. Q. Wong et al. CANCER RESEARCH
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline
- (2015) Celeste Lebbe et al. EUROPEAN JOURNAL OF CANCER
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
- (2015) Gerald Goh et al. Oncotarget
- Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
- (2015) Therese Phillips et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes
- (2014) Christopher A. Barker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Incidence and Survival for Merkel Cell Carcinoma in Queensland, Australia, 1993-2010
- (2014) Danny R. Youlden et al. JAMA Dermatology
- Effect of Host, Tumor, Diagnostic, and Treatment Variables on Outcomes in a Large Cohort With Merkel Cell Carcinoma
- (2014) Maryam M. Asgari et al. JAMA Dermatology
- Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma
- (2014) K. G. Paulson et al. Cancer Immunology Research
- Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
- (2013) C. A. Barker et al. Cancer Immunology Research
- Systemic Immune Suppression Predicts Diminished Merkel Cell Carcinoma–Specific Survival Independent of Stage
- (2012) Kelly G. Paulson et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Advances in Merkel cell carcinoma pathogenesis and management: a recently discovered virus, a new international consensus staging system and new diagnostic codes
- (2011) E. Nicolaidou et al. BRITISH JOURNAL OF DERMATOLOGY
- An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells
- (2011) Roland Houben et al. INTERNATIONAL JOURNAL OF CANCER
- Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator
- (2011) Masahiro Shuda et al. JOURNAL OF CLINICAL INVESTIGATION
- Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival
- (2011) Kelly G. Paulson et al. JOURNAL OF CLINICAL ONCOLOGY
- Merkel cell carcinoma: The prognostic implications of an occult primary in stage IIIB (nodal) disease
- (2011) Matthew Foote et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Merkel cell carcinoma - pathogenesis, clinical aspects and treatment
- (2011) D. Schrama et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- PD-L2 is expressed on activated human T cells and regulates their function
- (2011) Nassima Messal et al. MOLECULAR IMMUNOLOGY
- Immunobiology of Merkel Cell Carcinoma: Implications for Immunotherapy of a Polyomavirus-Associated Cancer
- (2011) Shailender Bhatia et al. Current Oncology Reports
- Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients
- (2010) K. G. Paulson et al. CANCER RESEARCH
- Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system
- (2010) Bianca D. Lemos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Merkel Cell Polyomavirus-Infected Merkel Cell Carcinoma Cells Require Expression of Viral T Antigens
- (2010) R. Houben et al. JOURNAL OF VIROLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Merkel cell cancer: update on biology and treatment
- (2009) Patricia Tai CURRENT OPINION IN ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Frequent Detection of Merkel Cell Polyomavirus in Human Merkel Cell Carcinomas and Identification of a Unique Deletion in the VP1 Gene
- (2008) A. Kassem et al. CANCER RESEARCH
- Clinical immunotoxicity of therapeutic proteins
- (2008) Jacques Descotes et al. Expert Opinion on Drug Metabolism & Toxicology
- Merkel Cell Polyomavirus Is More Frequently Present in North American than Australian Merkel Cell Carcinoma Tumors
- (2008) Kelly M. Garneski et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- MC Polyomavirus Is Frequently Present in Merkel Cell Carcinoma of European Patients
- (2008) Jürgen C. Becker et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
- (2008) H. Feng et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now